Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 6/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 6/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.46 |
| ▸ | USP7 | Q93009 | 1/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10401308 | 0.83 | SMN1; SMN2 (0.57) | VCAM1SMN1; SMN2TSHRCASP1KDM4E | |
| SCHEMBL17099927 | 0.81 | ADRA1D (0.49) | GABRA1GABRG2GABRB3GABRB2VCAM1 | |
| SCHEMBL12078300 | 0.81 | ABL1 (0.58) | CA12CA9SMN1; SMN2GAAKDM4E | |
| SCHEMBL8670727 | 0.79 | KDM4E (0.45) | GABRA1GABRG2GABRB3GABRB2SMN1; SMN2 | |
| SCHEMBL8757233 | 0.79 | SMN1; SMN2 (0.41) | SMN1; SMN2GAAKDM4EL3MBTL1 | |
| SCHEMBL16051600 | 0.78 | CYP1A2 (0.49) | MAOBSMN1; SMN2KDM4EL3MBTL1 | |
| SCHEMBL14620529 | 0.78 | KDM4E (0.49) | SMN1; SMN2GAAKDM4EL3MBTL1 | |
| SCHEMBL2071742 | 0.76 | KDM4E (0.43) | USP7SMN1; SMN2TMPRSS4GAAKDM4E | |
| SCHEMBL20117002 | 0.76 | ALDH1A1 (0.50) | CA12CA9MAOBSMN1; SMN2TSHR | |
| SCHEMBL8671847 | 0.75 | ALDH1A1 (0.59) | MAOBSMN1; SMN2GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2781519-B1 | NOVEL ANTIVIRAL PYRROLOPYRIDINE DERIVATIVE AND A PRODUCTION METHOD FOR SAME | ST PHARM CO LTD (KR) | 2019-10-30 | — | — | EP | disclosed |
| US-9499537-B2 | Antiviral pyrrolopyridine derivatives and method for preparing the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2016-11-22 | — | — | US | disclosed |
| EP-2781519-A1 | NOVEL ANTIVIRAL PYRROLOPYRIDINE DERIVATIVE AND A PRODUCTION METHOD FOR SAME | Korea Research Institute of Chemical Technology (KR) | 2014-09-24 | — | — | EP | disclosed |
| US-20140249162-A1 | NOVEL ANTIVIRAL PYRROLOPYRIDINE DERIVATIVES AND METHOD FOR PREPARING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2014-09-04 | — | — | US | disclosed |
| US-8034940-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-11 | — | — | US | disclosed |
| EP-2049507-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AND/OR AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | Brystol-Myers Squibb Company (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20090075995-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-19 | — | — | US | disclosed |
| WO-2008021926-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AND/OR AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249162-A1 | NOVEL ANTIVIRAL PYRROLOPYRIDINE DERIVATIVES AND METHOD FOR PREPARING THE SAME | MAVS, IMPDH1, SARS1 | GABRA1 3530/4885GABRG2 3793/4885GABRB3 3941/4885 |
| US-20090075995-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFKB2, NFRKB, NFKB1 | GABRA1 1331/4885GABRG2 2536/4885GABRB3 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.